- Home
- CMRX vs CGTX Comparison
CMRX vs CGTX Comparison
Compare CMRX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRX
- CGTX
- Stock Information
- Founded
- CMRX 2000
- CGTX 2007
- Country
- CMRX United States
- CGTX United States
- Employees
- CMRX N/A
- CGTX N/A
- Industry
- CMRX Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CMRX Health Care
- CGTX Health Care
- Exchange
- CMRX Nasdaq
- CGTX Nasdaq
- Market Cap
- CMRX 77.1M
- CGTX 79.3M
- IPO Year
- CMRX 2013
- CGTX 2021
- Fundamental
- Price
- CMRX $0.86
- CGTX $0.46
- Analyst Decision
- CMRX Strong Buy
- CGTX Buy
- Analyst Count
- CMRX 1
- CGTX 6
- Target Price
- CMRX $11.00
- CGTX $8.00
- AVG Volume (30 Days)
- CMRX 282.9K
- CGTX 633.0K
- Earning Date
- CMRX 11-07-2024
- CGTX 11-13-2024
- Dividend Yield
- CMRX N/A
- CGTX N/A
- EPS Growth
- CMRX N/A
- CGTX N/A
- EPS
- CMRX N/A
- CGTX N/A
- Revenue
- CMRX $159,000.00
- CGTX N/A
- Revenue This Year
- CMRX $1,772.84
- CGTX N/A
- Revenue Next Year
- CMRX N/A
- CGTX N/A
- P/E Ratio
- CMRX N/A
- CGTX N/A
- Revenue Growth
- CMRX N/A
- CGTX N/A
- 52 Week Low
- CMRX $0.75
- CGTX $0.34
- 52 Week High
- CMRX $1.30
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- CMRX 41.07
- CGTX 43.54
- Support Level
- CMRX $0.91
- CGTX $0.48
- Resistance Level
- CMRX $1.12
- CGTX $0.62
- Average True Range (ATR)
- CMRX 0.09
- CGTX 0.05
- MACD
- CMRX -0.01
- CGTX 0.00
- Stochastic Oscillator
- CMRX 10.31
- CGTX 11.92
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.